Page 72 - TD-4-1

Tumor Discovery Drug repurposing for pancreatic cancer via AI

two drugs, their interaction in clinical treatment for PDAC 2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB,
still requires further clinical and experimental verification. Fleshman JM, Matrisian LM. Projecting cancer incidence
and deaths to 2030: The unexpected burden of thyroid,
Conclusion liver, and pancreas cancers in the United States. Cancer Res.
2014;74(11):2913-2921.
In conclusion, we integrated systems biology methods
with deep learning techniques to systematically repurpose doi: 10.1158/0008-5472.Can-14-0155
existing drugs for PDAC therapy. By utilizing systems biology 3. Rahib L, Wehner MR, Matrisian LM, Nead KT. estimated
to identify drug targets through large-scale databases and projection of US cancer incidence and death to 2040. JAMA
genome-wide microarray data from both PDAC and non- Netw Open. 2021;4(4):e214708.
PDAC samples, and applying deep learning for the DTI doi: 10.1001/jamanetworkopen.2021.4708
model to identify potential molecular drugs based on three 4. Strobel O, Lorenz P, Hinz U, et al. Actual five-year survival
drug design specifications, we have developed a systematic after upfront resection for pancreatic ductal adenocarcinoma:
approach to accelerate drug development for PDAC. We Who beats the odds? Ann Surg. 2022;275(5):962-971.
hope that this drug repurposing strategy can be applied to
other diseases in the future, further advancing the field of doi: 10.1097/sla.0000000000004147
systems drug development. 5. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics
2020: GLOBOCAN estimates of incidence and mortality
Acknowledgments worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2021;71(3):209-249.
None.
doi: 10.3322/caac.21660
Funding 6. Lynch SM, Vrieling A, Lubin JH, et al. Cigarette smoking
None. and pancreatic cancer: A pooled analysis from the
pancreatic cancer cohort consortium. Am J Epidemiol.
Conflict of interest 2009;170(4):403-413.
The authors declare they have no competing interests. doi: 10.1093/aje/kwp134
7. Mela A, Rdzanek E, Tysarowski A, et al. The impact of
Author contributions changing the funding model for genetic diagnostics and
improved access to personalized medicine in oncology.
Conceptualization: All authors Expert Rev Pharmacoecon Outcomes Res. 2023;23(1):43-54.
Formal analysis: All authors
Investigation: Yi-Hsin Tsai doi: 10.1080/14737167.2023.2140139
Methodology: All authors 8. Park W, Chawla A, O’Reilly EM. Pancreatic cancer: A review.
Writing – original draft: Yi-Hsin Tsai JAMA. 2021;326(9):851-862.
Writing – review & editing: All authors doi: 10.1001/jama.2021.13027
Ethics approval and consent to participate 9. Elsayed M, Abdelrahim M. The latest advancement in
pancreatic ductal adenocarcinoma therapy: A review article
Not applicable. for the latest guidelines and novel therapies. Biomedicines.
2021;9(4):389.
Consent for publication
doi: 10.3390/biomedicines9040389
Not applicable.
10. Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C,
Availability of data Yang H. Chemoresistance in pancreatic cancer. Int J Mol Sci.
2019;20(18):4504.
The RNA-sequencing datasets from PDAC patients and doi: 10.3390/ijms20184504
healthy controls can be obtained from GSE183795 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE183795, 11. Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early
accessed on 10 March 2023). drug discovery. Br J Pharmacol. 2011;162(6):1239-1249.
doi: 10.1111/j.1476-5381.2010.01127.x
References
12. Weaver MF, Hopper JA, Gunderson EW. Designer drugs
1. Ma Y, Wu Q, Li X, Gu X, Xu J, Yang J. Pancreatic cancer: 2015: Assessment and management. Addict Sci Clin Pract.
From bench to bedside. Ann Transl Med. 2016;4(23):458. 2015;10(1):8.
doi: 10.21037/atm.2016.11.57 doi: 10.1186/s13722-015-0024-7

Volume 4 Issue 1 (2025) 64 doi: 10.36922/td.4709